Fundamental Data for SVA

Sonovac Biotech Ltd. specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as hepatitis A and hepatitis B, influenza, `SARS`, and avian flu. Sinovac is one of the leading emerging biotechnology companies in China.

# Employees: 0

Address: ,,,

Phone:

Fax:

Website:

Email:

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

No Information

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 4/8/2010

Mean EPS (Next Qtr): $0.25

Mean EPS (Year): $0.50

Mean Estimate(Long Term): $29.00

P/E Ratio(Based on EPS estimate): 14.950

Number of Estimates: 2

Shares Performance

Period	SVA	Compare to S&P
YTD	447.10 %	352.79 %
4 Weeks	0.80 %	-0.29 %
12 Weeks	19.46 %	12.63 %

Shares Information

Analyst Coverage: Y

Avg Volume: 2931694

Shares Outstanding: 42M

Market Cap: $0.32B

52 Week High: $10.46

52 Week Low: $0.85

P/E Ratio: 23.590

PEG Ratio: 0.520

Split: On 1/1/1990 SVA split by factor of 0.020

Earnings Performance

EPS Growth in Last Quarter: -14.29 %

EPS Growth in Last Year: 500.00 %

Sales Growth in Last Quarter: 6.03 %

Sales Growth in Last Quarter: 142.46 %

Financials

Qtr Book Value: $4.53

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 5.320